# US 2025/0205253 A1 · Pharmaceutical composition for preventing or treating benign prostatic hyperplasia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205253 A1
- Document ID: US20250205253A1
- Status: Published application
- Kind: A1
- Application number: 18/798,210
- Filed: 2024-08-08
- Published: 2025-06-26
- Earliest claimed: 2023-12-22
- Assignees: University-Industry Cooperation Group of Kyung Hee University
- Applicants: University-Industry Cooperation Group of Kyung Hee University
- Inventors: HYO-JIN AN; BO-RAM JIN
- Web page: https://patentgrep.com/patent/US20250205253A1

## CPC

- A61K 31/66: Phosphorus compounds
- A61P 13/08: of the prostate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a pharmaceutical composition, a health functional food, and a method for preventing or treating benign prostatic hyperplasia (BPH). The present invention includes mitoquinone as an active ingredient and inhibits the androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways to alleviate pathological prostatic hypertrophy and exhibit anti-proliferative and antioxidant effects. Therefore, it can be effectively used in preventing, treating, or ameliorating BPH.

## Claims

### Claim 1

A pharmaceutical composition for preventing or treating benign prostatic hyperplasia (BPH), comprising mitoquinone or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the mitoquinone is included at 25 μM or more.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the mitoquinone inhibits androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the mitoquinone inhibits dihydrotestosterone (DHT)-induced prostate cell proliferation.

### Claim 5

A health functional food for preventing or ameliorating benign prostatic hyperplasia (BPH), comprising mitoquinone or a stiologically acceptable salt thereof.

### Claim 6 (depends on 5)

The health functional food of claim 5, wherein the mitoquinone is included at 25 μM or more.

### Claim 7 (depends on 5)

The health functional food of claim 5, wherein the mitoquinone inhibits androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways.

### Claim 8 (depends on 5)

The health functional food of claim 5, wherein the mitoquinone inhibits dihydrotestosterone (DHT)-induced prostate cell proliferation.

### Claim 9

A method of treating benign prostatic hyperplasia (BPH), the method comprising administering to a patient in need of treatment mitoquinone, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including mitoquinone.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mitoquinone is included at 25 μM or more.

### Claim 11 (depends on 9)

The method of claim 9, wherein the mitoquinone inhibits androgen receptor (AR) and nucleotide oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) signaling pathways.

### Claim 12 (depends on 9)

The method of claim 9, wherein the mitoquinone inhibits dihydrotestosterone (DHT)-induced prostate cell proliferation.

### Claim 13 (depends on 9)

The method of claim 9, wherein the administering is performed parenterally or orally.
